Clinical Trial Detail

NCT ID NCT02954874
Title Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

triple-receptor negative breast cancer

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.